IAAF approves application of three Russians to compete as neutral athletesSport February 24, 1:43
US lawmakers present no evidence of Russia’s interference in US election - Russian MPRussian Politics & Diplomacy February 23, 21:42
Russia to continue strengthen its Armed Forces - PutinRussian Politics & Diplomacy February 23, 21:37
4,000 Russian nationals fight among militants in Syria - PutinRussian Politics & Diplomacy February 23, 21:31
Opposition’s demand of Assad’s immediate resignation absurd - Russian envoy to GenevaRussian Politics & Diplomacy February 23, 16:34
Moscow celebrates Defender of the Fatherland DaySociety & Culture February 23, 16:19
ISS astronauts capture Dragon with manipulatorScience & Space February 23, 14:36
Vitaly Churkin’s body delivered to RussiaRussian Politics & Diplomacy February 23, 12:30
Ukrainian military shell Donetsk water purification plantWorld February 23, 11:45
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.